HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: Challenges and opportunities

Research output: Contribution to journalArticlepeer-review

Abstract

Allogenic hematopoietic stem cell recipients may have preformed antibodies directed against foreign HLA antigens. The use of partially HLA-mismatched allogeneic hematopoietic stem cell donors allows for the possibility of the presence of circulating HLA donor-specific antibodies (DSAs) in the recipient. The presence of DSAs at the time of stem cell infusion increases the risk of primary graft failure. More recently developed technology using solid phase immunoassays (SPIs) with fluorochrome-conjugated beads has greatly improved the ability to detect and classify DSAs. When used in combination with the classic lymphocytotoxic complement-dependent and flow cytometric crossmatch tests, SPIs help provide DSA strength assessment. Parous females frequently harbor DSAs. DSAs tend to be of higher intensity when directed against haploidentical first-degree relatives. DSA assessment requires frequent monitoring as their relative strength can change over time. Although the criteria that constitutes a prohibitive DSA is unknown, desensitization techniques can result in engraftment rates as experienced in fully HLA-matched allogeneic blood or marrow transplantation recipients.

Original languageEnglish (US)
Pages (from-to)645-650
Number of pages6
JournalHematology
Volume2017
Issue number1
DOIs
StatePublished - Dec 8 2017

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: Challenges and opportunities'. Together they form a unique fingerprint.

Cite this